UNASSIGNED: Due to the inability of classical chemotherapeutic agents to exclusively target @entity5 cells, these treatments are associated with severe @entity137 profiles. Thus, long-circulating liposomes have been developed in the past to enhance accumulation in @entity5 tissue by passive targeting. Accordingly, commercially available liposomal formulations of sterically stabilized liposomal @entity632 (Caelyx  , @entity632  , Lipodox  ) are associated with improved off-target profiles. However, these preparations are still not capable to selectively bind to target cells. Thus, in an attempt to further optimize existing treatment schemes immunoliposomes have been established to enable active targeting of @entity5 tissues. Recently, we have provided evidence for therapeutic efficacy of anti- @entity2856 -targeted, surface modified @entity632 loaded liposomes. Our approach involved a technique, which allows specific post-modifications of the liposomal surface by primed antibody-anchor conjugates thereby facilitating personalized approaches of commercially available liposomal drugs. In the current study, post-modification of sterically stabilized liposomal @entity3105 was thoroughly investigated including the influence of different modification techniques ( @entity558 , SPIT, SPIT60), lipid composition ( @entity4203 /Chol, @entity57599 /Chol), and buffers (HBS, SH). As earlier in vivo experiments did not take into account the presence of non-integrated ab-anchor conjugates this was included in the present study. Our experiments provide evidence that post-modification of commercially available liposomal preparations for active targeting is possible. Moreover, lyophilisation represents an applicable method to obtain a storable precursor of surface modifying antibody-anchor conjugates. Thus, these findings open up new approaches in @entity1 individualized targeting of chemotherapeutic therapies.

Liposomal XXXX for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo - challenges and prospects.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin', 'Doxil'] @entity1 :: ('9606', 'Species') :: ['patient'] @entity558 :: ('MESH:C536528', 'Disease') :: ['PIT'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity57599 :: ('5688', 'Gene') :: ['HSPC'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity4203 :: ('5541', 'Gene') :: ['SPC'] @entity3105 :: ('D004317', 'Chemical') :: ['Dox'] @entity2856 :: ('3480', 'Gene') :: ['IGF1R']
@entity632 :: (MESH:D004317,Chemical) :: ['doxorubicin']
